Menu Search
Equities

Anixa Biosciences Inc

  • Add to watchlist
  • Add to portfolio
CY71:DEU

Anixa Biosciences Inc

Actions
  • Price (EUR)2.74
  • Today's Change-0.02 / -0.72%
  • Shares traded216.00
  • 1 Year change+31.73%
  • Beta0.4465
Data delayed at least 15 minutes, as of Jul 04 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.

  • Revenue in USD (TTM)0.00
  • Net income in USD-12.13m
  • Incorporated1982
  • Employees5.00
  • Location
    Anixa Biosciences Inc3150 Almaden Expy Ste 250SAN JOSE 95118United StatesUSA
  • Phone+1 (408) 708-9808
  • Fax+1 (302) 655-5049
  • Websitehttps://www.anixa.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.